UK: NICE Fees Plan Would Cost Life Sciences Industry £10m Each Year
England’s department of health is again consulting on plans to allow health technology appraisal body NICE to charge companies for conducting appraisals.
You may also be interested in...
Fees for appraisals that the health technology assessment body, NICE, will introduce in April could adversely impact companies with medicines for smaller indications, despite a bigger fee reduction for some manufacturers.
UK health technology body NICE will wait for the government to finalize its life sciences strategy before deciding on whether to go ahead with its plan to levy a fee for technology appraisals. Pharmaceutical and medtech companies say the delay will allow more time for their concerns over the proposal to be explored.
A proposal by the UK's HTA body NICE to charge companies for technology appraisals has raised several issues, such as the need for reforms to the HTA process, ensuring independence and credibility of appraisals, greater accountability and transparency at NICE, and the impact of fees on bringing new medicines to market.